Document Purchase Start date : 19 Jul 2019
Rapid-acting insulins (insulin aspart [NovoLog[R]], insulin lispro [Humalog[R]], insulin glulisine
[Apidra[R]]) are preferred for mealtime coverage and correction of hyperglycemia (ADA, 2016; Freeland, 2016).
Subcutaneously injected insulin, even the rapid-acting insulin analogs (insulin aspart, insulin glulisine
, and insulin lispro), are absorbed slowly enough into systemic circulation that the insulin concentration can remain elevated up to 6 hours after dosing.
2015.Effects of rapid-acting insulin analogues insulin glulisine
and insulin aspart on postprandial glycemic excursion with single bout of exercise in patients with type 2 diabetes.
This has been exploited in the genetic engineering of insulin analogues used in rapid-acting insulin preparations (insulin aspart, insulin lispro, and insulin glulisine
), which have substitutions or minor alterations in the amino acid sequence relative to human insulin .
Scholtz, "Insulin glulisine
, a new rapid-acting insulin analogue, displays a rapid time-action profile in obese nondiabetic subjects," Experimental and Clinical Endocrinology & Diabetes, vol.
Adjust to target in type 2 diabetes: comparison of a simple algorithm with carbohydrate counting for adjustment of mealtime insulin glulisine
. Diabetes Care.
the addition of rapid-acting insulin glulisine
with or without metformin injected once daily at the time of the patient's main meal (basal-plus), or three times daily at meal time (basal-bolus).
The product, which delivers 1 to 30 units per injection, can be used with Lantus (insulin glargine), Apidra (insulin glulisine
) or Insuman (recombinant human insulin).
The company said that the study found that using two regimens including Lantus (insulin glargine [rDNA origin] injection) and Apidra (insulin glulisine
[rDNA origin] injection) lowered blood glucose levels compared to premixed insulin with less hypoglycaemia and improvement in diabetes-specific quality of life.
is marketing Apidra SoloSTAR (insulin glulisine
[rDNA origin] injection), a prefilled disposable pen that contains the rapid-acting insulin analog Apidra.
The Food and Drug Administration approved a new pediatric indication for Apidra (insulin glulisine
[rDNA origin] solution for injection).